Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 12/20 | 0.54 |
| ▸ | HTR1A | P08908 | 2/20 | 0.47 |
| ▸ | HTR2C | P28335 | 2/20 | 0.47 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.47 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.47 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.47 |
| ▸ | HRH1 | P35367 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8870642 | 0.88 | SIGMAR1 (0.50) | SIGMAR1HTR1AHTR2CTMEM97ADRA2A | |
| SCHEMBL8870103 | 0.82 | SIGMAR1 (0.53) | SIGMAR1HTR1AHTR2C | |
| SCHEMBL8948259 | 0.77 | SIGMAR1 (0.68) | SIGMAR1HTR1AHTR2CTMEM97ADRA2A | |
| SCHEMBL8109676 | 0.77 | SIGMAR1 (0.59) | SIGMAR1HTR1AHTR2C | |
| SCHEMBL8948162 | 0.76 | SIGMAR1 (0.69) | SIGMAR1HTR1AHTR2CTMEM97ADRA2A | |
| SCHEMBL7761660 | 0.75 | CXCR4 (0.44) | HTR1AHTR2C | |
| SCHEMBL9484568 | 0.75 | SIGMAR1 (0.62) | SIGMAR1HTR1AHTR2CADRA2AADRA2B | |
| SCHEMBL9437994 | 0.75 | SIGMAR1 (0.54) | SIGMAR1HTR1AHTR2C | |
| SCHEMBL8948196 | 0.74 | SIGMAR1 (0.61) | SIGMAR1HTR1AHTR2C | |
| SCHEMBL9659159 | 0.74 | SIGMAR1 (0.53) | SIGMAR1HTR1AHTR2CADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170246159-A1 | BENZOQUINOLONE INHIBITORS OF VMAT2 | AUSPEX PHARMACEUTICALS INC (US) | 2017-08-31 | — | — | US | disclosed |
| CN-1050601-C | Preparation and the pharmaceutical compositions which contain them | ADIR (FR) | 2000-03-22 | — | — | CN | disclosed |
| US-5512569-A | SIGMA RECEPTOR DISORDERS; PSYCHOLOGICAL DISORDERS | ADIR ET COMPAGNIE (FR) | 1996-04-30 | — | — | US | disclosed |
| CN-1111626-A | Preparation and the pharmaceutical compositions which contain them | ADIR (FR) | 1995-11-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170246159-A1 | BENZOQUINOLONE INHIBITORS OF VMAT2 | ACAT2, CPT1A, SLC18A2 | SIGMAR1 616/4885HTR1A 747/4885HTR2C 577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.